Ninety One UK 13F: Cuts Boston Scientific (BSX) Stake by $152M
A recent regulatory filing shows Ninety One UK cut its holdings in Boston Scientific Corporation by a wide margin.
Reviewed by automated data checks against the source filing. How we make and check alerts
Ninety One UK sold 3,484,327 shares from its stake in Boston Scientific Corporation ($BSX), a 99.50% decrease, according to a 13F filing with the SEC dated October 15, 2026. It reported 17,658 shares worth $770,772 at the end of the quarter.
Since the filing, $BSX is up 0.6% to date (from the $44.14 close on Oct 15, 2026).
BSX
Boston Scientific Corporation
Key Points
- Ninety One UK filed a form 13F showing a 99.5% reduction in its Boston Scientific Corporation stake, shedding 3,484,327 shares.
- Ninety One UK held 17,658 $BSX shares at quarter end, down 99.50% from the prior quarter.
- The medical device maker trades recently around $44.20, positioned well below its 50-day and 200-day moving averages.
- Boston Scientific generated $21.0 billion in trailing-twelve-month revenue with a net profit margin of 17.5%.
Get $BSX trade alerts by text
We text you when insiders, Congress or big funds trade $BSX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Boston Scientific Corporation alert may contain errors. Disclosures
Ninety One UK significantly scaled back its holdings in Boston Scientific Corporation (NYSE: BSX) according to a Form 13F filing with the SEC filed on October 15, 2026. Keep in mind that 13F filings look backward at the previous quarter and might not reflect the fund's current holdings.
What Changed in Ninety One UK's Boston Scientific Position
Ninety One UK trimmed its position by 3,484,327 shares, resulting in a 99.5% decrease from the previous quarter. The firm ended the period with 17,658 shares of Boston Scientific. The remaining stake carried a reported value of about $770,772.
Other Institutional Activity in Boston Scientific
Other large investors also adjusted their positions in Boston Scientific during the quarter. Blackrock Inc. reduced its holdings by 2,135,425 shares, ending with 129,680,916 shares worth about $5.76 billion. Vanguard Capital Management LLC grew its holdings by 674,889 shares, ending with 97,087,553 shares worth about $4.31 billion. State Street Corporation added 2,121,285 shares to hold 70,111,196 shares valued at roughly $3.11 billion. Primecap Management Company grew its stake by 17,991,834 shares, finishing with 50,520,914 shares worth about $2.24 billion. Meanwhile, FMR, LLC cut 28,526,236 shares, leaving it with 45,702,845 shares valued at about $2.03 billion.
Boston Scientific Corporation Stock Up 2.8%
Boston Scientific shares recently traded around $44.20. The stock sits below its 50-day moving average of $46.18 and well under its 200-day moving average of $59.36. Shares rest closer to its 52-week low of $41.39 than its 52-week high of $105.65.
Recent Earnings
Boston Scientific reported trailing-twelve-month revenue of $21.0 billion and earnings of $2.47 per share. The company posted a net profit margin of 17.5% and a return on equity of 15.3%. Boston Scientific reports its next financial results on October 28, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
12 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 0.7%. Revenue met estimates.
-
Profit surprise
EBITDA met by 0 percent. Operating income missed by 13 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 12 target cuts.
-
Earnings quality
Gross margin up 6.2 points. Operating margin up 1.4 points. Positive free cash flow.
Earnings Call Summary
Boston Scientific reported first quarter sales of $5.2 billion, up 9.4 percent, and beat on earnings at $0.80 per share. However, management revealed major headwinds in three key franchises. The EP cardiology ablation business, which grew 22 percent this quarter, is now expected to slow to 10 percent full year as competition from Medtronic, J and J, and Abbott pressures U.S. share. WATCHMAN, which grew 19 percent, slowed sharply in February as stand-alone procedures fell even as concomitant adoption grew. Urology nearly flatlined at 1 percent growth due to problems in stone management and sacral neuromodulation. Management said the company lost more market share than expected and hospital capacity constraints are limiting WATCHMAN procedure volume.
Guidance The company cut its full year sales growth guidance from an expected 8 to 10 percent range down to 6.5 to 8 percent. They expect second quarter sales to grow only 5 to 7 percent year over year. The company now guides full year earnings per share to $3.34 to $3.41, still up 9 to 11 percent but well below prior expectations.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Insider Buying and Selling at Boston Scientific Corporation
Insiders executed multiple transactions ahead of the filing, including purchases by Chief Executive Officer Michael F. Mahoney and director Susan E. Morano.
Analysts Set New Price Targets
Wall Street firms updated their views on the stock recently, with analysts holding a consensus buy rating and a mean price target of $59.24.
About Boston Scientific
Boston Scientific Corporation designs and builds medical devices used across various interventional medical specialties worldwide. The company operates through two major units, MedSurg and Cardiovascular, providing tools utilized by physicians in hospitals and clinics globally. Institutional portfolio shifts in the medical device maker often draw interest as health sector trends evolve.
Bottom Line
Investors should review Boston Scientific's upcoming earnings report on October 28, 2026 for fresh details on operational performance. As always, 13F data captures a snapshot from a prior period and doesn't guarantee current positioning. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.
Related Filing Alerts
Source: Ninety One UK's 13F filing on $BSX (Oct 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Ninety One UK 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts